{
    "clinical_study": {
        "@rank": "100912", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "description": "Everolimus and exemestane"
        }, 
        "brief_summary": {
            "textblock": "An observational study in patients with advanced ER+, HER2 negative breast cancer, who are\n      treated with everolimus and exemestane in combination. The objective of the study is to\n      assess the safety pattern of everolimus in a real world setting."
        }, 
        "brief_title": "Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who are\n             treated with everolimus and exemestane according to the approved Summary of Product\n             Characteristics (SmPC).\n\n          -  Patients who started treatment after approval of this indication but before the\n             initiation of this study can be retrospectively included, provided that they have\n             systematically been assessed for adverse events.\n\n          -  The decision to treat the patient with everolimus and exemestane must be independent\n             of the patient's participation in the study.\n\n          -  The patient must provide signed Informed Consent before any data can be captured.\n\n        Exclusion Criteria:\n\n        - No formal exclusion criteria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who are\n        treated with everolimus and exemestane according to the approved SmPC will be included in\n        the study."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023359", 
            "org_study_id": "CRAD001JDK02"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "intervention_name": "Everolimus and exemestane", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced breast cancer", 
            "Everolimus"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "erik.hugger.jakobsen@rsyd.dk", 
                    "last_name": "Erik Hugger Jakobsen, MD", 
                    "phone": "+45 79406015"
                }, 
                "contact_backup": {
                    "email": "birgitte.uhd@rsyd.dk", 
                    "last_name": "Birgitte Uhd", 
                    "phone": "+45 79182235"
                }, 
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark", 
                        "zip": "6700"
                    }, 
                    "name": "Onkologisk Afdelning, SVS Esbjerg"
                }, 
                "investigator": {
                    "last_name": "Erik Hugger Jakobsen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marianne.ewertz@rsyd.dk", 
                    "last_name": "Marianne Ewertz, Prof.", 
                    "phone": "+45 6541 1536"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "Department of Oncology, Odense University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Dataprotection Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 2.5 years"
            }, 
            {
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2.5 years"
            }, 
            {
                "measure": "Clinical benefit rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 2.5 years"
            }, 
            {
                "measure": "Time on treatment with everolimus", 
                "safety_issue": "No", 
                "time_frame": "Up to 2.5 years"
            }, 
            {
                "measure": "Reason for stopping treatment with everolimus", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2.5 years"
            }
        ], 
        "source": "Novartis Healthcare A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Healthcare A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}